65
Structure Therapeutics GPCRsaid on Monday that its obesity drug showed up to 11.3% weight loss after 36 weeks of treatment in a mid-stage study.
Analysts at BMO Capital Markets and HC Wainwright predicted that alleniglyprone tablets would result in weight loss of more than 10 percent.
Biotechnology companies are currently working with Novo Nordisk.[NOVOb.CO]) and Eli Lilly as they compete for a share of the lucrative obesity treatment market, estimated to be worth $150 billion annually by the early 2030s.
Another study using high-dose alleniglyprone showed weight loss of up to 15.3% at 36 weeks.
